1. Home
  2. XTNT vs CING Comparison

XTNT vs CING Comparison

Compare XTNT & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xtant Medical Holdings Inc.

XTNT

Xtant Medical Holdings Inc.

HOLD

Current Price

$0.44

Market Cap

61.7M

Sector

Health Care

ML Signal

HOLD

CING

Cingulate Inc.

HOLD

Current Price

$5.34

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XTNT
CING
Founded
N/A
2012
Country
United States
United States
Employees
N/A
14
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.7M
64.5M
IPO Year
2009
N/A

Fundamental Metrics

Financial Performance
Metric
XTNT
CING
Price
$0.44
$5.34
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$1.00
$34.50
AVG Volume (30 Days)
74.0K
168.9K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
125.00
N/A
EPS
N/A
N/A
Revenue
$53,337,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$9.30
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.39
$3.16
52 Week High
$0.95
$11.89

Technical Indicators

Market Signals
Indicator
XTNT
CING
Relative Strength Index (RSI) 53.48 57.73
Support Level $0.44 $4.80
Resistance Level $0.49 $5.15
Average True Range (ATR) 0.03 0.28
MACD 0.00 0.05
Stochastic Oscillator 54.58 94.15

Price Performance

Historical Comparison
XTNT
CING

About XTNT Xtant Medical Holdings Inc.

Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: